statistiche ricercatore

TOSI, GIOVANNA

Distribuzione geografica

Continente	#
NA - Nord America	11.818
EU - Europa	8.817
AS - Asia	5.326
SA - Sud America	496
AF - Africa	67
Continente sconosciuto - Info sul continente non disponibili	8
OC - Oceania	6
Totale	26.538

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	11.604
IT - Italia	4.341
SG - Singapore	1.676
UA - Ucraina	1.555
CN - Cina	1.220
VN - Vietnam	892
TR - Turchia	654
DE - Germania	589
SE - Svezia	577
HK - Hong Kong	565
FI - Finlandia	477
BR - Brasile	435
FR - Francia	315
IE - Irlanda	298
GB - Regno Unito	251
RU - Federazione Russa	243
CA - Canada	138
IN - India	100
MX - Messico	57
BD - Bangladesh	46
PL - Polonia	42
JP - Giappone	41
BE - Belgio	32
NL - Olanda	26
ZA - Sudafrica	26
ES - Italia	22
IQ - Iraq	20
AR - Argentina	19
PK - Pakistan	14
KR - Corea	12
LT - Lituania	11
MA - Marocco	11
AE - Emirati Arabi Uniti	10
EC - Ecuador	10
PH - Filippine	10
VE - Venezuela	9
EU - Europa	8
CH - Svizzera	7
IR - Iran	7
CZ - Repubblica Ceca	6
ID - Indonesia	6
KE - Kenya	6
MY - Malesia	6
NG - Nigeria	6
PE - Perù	6
PY - Paraguay	6
SA - Arabia Saudita	6
UZ - Uzbekistan	6
JO - Giordania	5
TN - Tunisia	5
TW - Taiwan	5
AT - Austria	4
CL - Cile	4
CO - Colombia	4
DZ - Algeria	4
JM - Giamaica	4
LB - Libano	4
MD - Moldavia	4
AU - Australia	3
BY - Bielorussia	3
EG - Egitto	3
IL - Israele	3
KH - Cambogia	3
NP - Nepal	3
PA - Panama	3
RS - Serbia	3
BH - Bahrain	2
CI - Costa d'Avorio	2
CR - Costa Rica	2
DO - Repubblica Dominicana	2
GA - Gabon	2
GR - Grecia	2
HN - Honduras	2
HR - Croazia	2
MT - Malta	2
NZ - Nuova Zelanda	2
PR - Porto Rico	2
PS - Palestinian Territory	2
TT - Trinidad e Tobago	2
UY - Uruguay	2
AO - Angola	1
AZ - Azerbaigian	1
BB - Barbados	1
BG - Bulgaria	1
DK - Danimarca	1
GE - Georgia	1
GY - Guiana	1
KW - Kuwait	1
KZ - Kazakistan	1
ME - Montenegro	1
MK - Macedonia	1
NO - Norvegia	1
OM - Oman	1
QA - Qatar	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
TG - Togo	1
TJ - Tagikistan	1
WS - Samoa	1
Totale	26.538

Salva come PNG Salva come JPEG

Città	#
Milan	3.337
Jacksonville	1.193
San Jose	1.074
Singapore	930
Fairfield	928
Ashburn	866
Chandler	783
Woodbridge	609
Hong Kong	557
Wilmington	429
Ann Arbor	424
Houston	410
Izmir	406
Princeton	398
Seattle	390
Beijing	367
Dearborn	366
Nyköping	297
Dublin	296
Dallas	292
Cambridge	287
Dong Ket	268
Boardman	236
The Dalles	235
Rome	234
Lauterbourg	173
Council Bluffs	157
San Mateo	138
New York	133
Los Angeles	106
Ho Chi Minh City	102
Como	91
Toronto	86
Helsinki	84
Chicago	80
Hanoi	79
San Diego	77
Ogden	69
Orem	69
Santa Clara	69
Guangzhou	59
Munich	53
São Paulo	53
Düsseldorf	45
Chennai	40
Tokyo	40
Warsaw	36
Hefei	35
Mexico City	34
Verona	33
Brussels	31
London	31
Manchester	29
Nanjing	28
Frankfurt am Main	26
Hangzhou	25
Norwalk	25
Shanghai	22
Turku	22
Boston	21
Kunming	21
Phoenix	21
Montreal	20
Pune	20
Amsterdam	19
Brooklyn	19
Denver	19
Johannesburg	19
Jinan	18
Falls Church	17
Stockholm	17
Da Nang	16
Fuzhou	16
San Francisco	16
Washington	16
Columbus	15
Shenzhen	15
St Petersburg	15
Atlanta	14
Haiphong	14
Poplar	14
Zhengzhou	12
Belo Horizonte	11
Mumbai	11
Nuremberg	10
Baghdad	9
Brasília	9
Buffalo	9
Changsha	9
Curitiba	9
Kocaeli	9
Ankara	8
Kilburn	8
Nanchang	8
Porto Alegre	8
Querétaro	8
Rio de Janeiro	8
Tianjin	8
Chongqing	7
Dhaka	7
Totale	18.342

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC class ii expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells	270
Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: A critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state	247
Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)	236
Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy	226
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	217
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1	217
Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression.	215
Typing of a polymorphic human gene conferring susceptibility to insulin-dependent diabetes mellitus by picosecond-resolved FRET on non-purified/non-amplified genomic DNA	212
Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	210
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	207
A girl with Diabetes and severe Combined Immunodeficiency from Adenosine Deaminase Deficiency	207
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	206
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	205
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	204
The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators	203
The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells	203
The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1	197
Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes	194
The MHC class II transactivator: prey and hunter in infectious diseases	191
Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	191
Autoimmunità e Malattie Autoimmuni	189
Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication	186
Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment	184
Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis	182
Assessment of the DQB1-DQA1 complete genotype allows best prediction for IDDM	179
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	178
Tumor Immunology meets Immunology: Modified cancer cells as professional APC for priming naÃ¯ve tumor-specific CD4+ T cells	178
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	176
The MHC class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation.	176
Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators	175
Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells	174
A dual defensive role of CIITA against retroviral infections	172
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1.	171
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma	169
Time-Resolved Förster Resonance Energy Transfer Analysis of Single-Nucleotide Polymorphisms: Towards Molecular Typing of Genes on Non-Purified and Non-PCR-Amplified DNA	167
New approaches of cancer vaccination and cancer immunotherapy based on the optimal stimulation of tumor-specific, MHC class II-restricted CD4+ T helper cells	166
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	164
MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?	164
Associazione tra genotipo HLA-DQ e suscettibilità al Diabete insulino-Dipendente	164
CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity	160
Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers	159
MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to and affecting Tax-2 intracellular localization	159
HLA-DQ genotype in early onset insulin dependent diabetes mellitus	158
The MHC-II transactivator CIITA inhibits Tat-mediated HIV-1 LTR transactivation and virus replication in human U937 monocytic cells	158
Tax-1-mediated HTLV-1 replication and NF-kB activation is inhibited by the MHC-II transactivator CIITA	158
Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes	158
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	157
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	157
Tax-1-mediated NF-kB activation is inhibited by the MHC-II transactivator CIITA	157
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	157
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	156
Tat protein is an HIV-1 encoded SS-chemochine homolog that promotes migrationand upregulates CCR3 on human FceRI+ cells	156
Analysis of microchimerism in thyroid autoimmune diseases	156
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	155
Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters	155
Apparente dissociazione tra fenotipo DR e genotipo MHC di classe II in IDDM	155
Molecular and Cellular Correlates of the CIITA-Mediated Inhibition of HTLV-2 Tax-2 Transactivator Function Resulting in Loss of Viral Replication.	152
Molecular typing of polymorphic genes by time-resolved fluorescence resonance energy transfer	151
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	150
The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein	148
Distinct subcellular localization of HTLV-1 HBZ oncoprotein in the ATL leukemic and HAM/TSP patients.	148
Role of the HLA-DQ genotype in IDDM susceptibility	147
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	147
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1	146
The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-kappa B by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein	146
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	144
The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication	144
HLA-DQB1 typing of north east italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-Enzyme Immunoassay (DEIA)	143
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	143
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	142
Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines	142
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	141
The MHC Class II transactivator, CIITA,is a viral restriction factor for human oncogenic retroviruses	141
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	141
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	141
The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for Insulin-Dependent Diabetes Mellitus	141
HTLV-2 Tax-2 transactivator increases the expression and the function of its inhibitor CIITA, the master regulator of HLA-II gene transcription	140
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	140
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	140
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	138
Associazione tra HLA-DQB1 e diabete giovanile analizzata a livello molecolare per Southern e DEIA	138
Cellular and molecular aspects of immune response relevant to autoimmune diseases	138
Expression of MHC class I and class II antigens in pancreatic adenocarcinomas	137
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic Virus Type 1	136
The constitutive activation of NF-kB by HTLV-1 Tax-1 oncoprotein is inhibited by the MHC class II transactivator CIITA	136
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	135
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	134
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	134
Host-retrovirus interaction: role of CIITA in the inhibition of HTLV-1 replication and oncogenic potential	134
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	131
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	130
Regulation of HLA antigen expression in HIV infected cells	130
Human T-cell leukemia virus type II directly acts on CD34+ hematopoietic precursors by increasing their survival potential. Envelope associated HLA class II molecules reverse this effect	129
The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication	127
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	126
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	126
Approcci immunogenetici per il controllo dell'infezione da retrovirus umani	126
Characterization of an epigenetic variant lacking MHC-II inducibility by IFN-g in the promyelocytic cell line THP-1	125
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity.	125
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	125
Totale	16.321

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	102.971
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	102.971

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2020/2021	532	0	0	0	0	0	0	0	0	0	0	0	532
2021/2022	1.700	211	223	152	133	42	48	57	123	83	222	159	247
2022/2023	2.159	252	86	120	258	159	493	0	292	312	63	69	55
2023/2024	4.884	816	801	919	824	877	310	50	40	155	20	9	63
2024/2025	2.562	10	45	483	50	107	108	123	141	313	158	220	804
2025/2026	6.064	492	363	187	862	539	448	1.407	371	620	413	246	116
Totale													26.604